GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc. 1 GORE VIABAHN ® Endoprosthesis Speaker’s.

Slides:

Advertisements

Similar presentations

PROSPECTIVE RANDOMIZED COMPARATIVE STUDY BETWEEN FEMORO-DISTAL BYPASS WITH PTFE AND HEPARIN-BONDED PTFE.

Advertisements

Aortic dissection: current percutaneous options Advanced Angioplasty BSET Jan 2008.

GORE ® VIABAHN ® Device for Arteriovenous Access (Revision) Speaker Slideset GORE ®, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates.

Andrew Bunney MD, PGY-4 University of Minnesota

Www. Clinical trial results.org The RAVEL Study A RAndomised (double blind) study with the Sirolimus coated BX™ VElocity balloon expandable stent (CYPHER™)

Viabahn Covered Stents for Cephalic Arch Stenosis Can Improve Patency and Longevity of Upper Arm AV Fistulas Toufic Safa, MD, FACS Vascular & Endovascular.

Superficial Femoral Artery Stents - Bare, Covered, or Drug-Coated – “The Data and The HYPE” Dennis F. Bandyk, MD Division of Vascular & Endovascular Surgery.

M.Unverdorben; TCT Problem The treatment of stenoses of small coronary arteries (SVD) and of restenoses after stent deployment (ISR) still show.

VIABAHN Endoprosthesis for Severe Femoropopliteal Lesions 舒畅 Dept. of Vascular Surgery, The 2nd Xiang-Ya Hospital, Central-South University 中南大学湘雅二医院血管外科.

Is There Still a Controversy About Stent Type for TASC C&D Lesions

Post-Surgical Care for the Individual With PAD: A Shared Responsibility to Sustain Life and Limb.

Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.

ATH: A Novel Heparin-Based Anticoagulant

Angelo Cioppa, MD  I have the following potential conflicts of interest to report:  Research contracts  Consulting  Employment in industry  Stockholder.

12-Month Analysis Barry T. Katzen MD, FACR, FACC Founder and Medical Director Baptist Cardiac & Vascular Institute.

A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.

A Comparison of the Moxy™ Drug Coated Balloon Catheter vs. Standard PTA for Femoropopliteal Disease NCT# MONTH RESULTS OF THE LEVANT I TRIAL.

D.DELEANU, M.CROITORU BUCHAREST, ROMANIA. BTK Interventions ? BTK disease = claudication and CLI BTK interventions = CLI Main goal of CLI therapy = functional.

Superficial Femoral Artery – Where Does the Data Stand? Director, Endovascular Services Mehdi H. Shishehbor, DO, MPH, PhD Cleveland Clinic.

Date of download: 7/7/2016 Copyright © The American College of Cardiology. All rights reserved. From: Heparin-Bonded Covered Stents Versus Bare-Metal Stents.

End points in PTCA trials. A successful angioplasty is defined as the reduction of a minimum stenosis diameter to

November 9, 2015 February 20, 2017 Using real world evidence – industry perspective Pma indication expansion Melissa hasenbank, phd Sr. Clinical Research.

The Placement of Stents Associated with Vascular Access

Global Experience with Peripheral DCBs/Stent Studies: C.R. Bard

The Endocross Enabler-P: First in-Human Results

Chapter 13 Evaluation of arterial bypass grafts and stents

Speaker’s Presentation

Can Drug-Coated Balloons Work in Synergy with Stent Grafts?

The Combination That Lasts

Iliac and Aortiliac Occlusions: Stent Grafts or Bare Metal Stents…

New Stent Designs Applicable for Renal Intervention

Lutonix® Paclitaxel-Coated Balloon to Treat Obstructive Lesions in the Superficial Femoral and Popliteal Arteries Preliminary Six-Month Results from.

Heavily calcified SFA lesions do not avoid the use of 4 F systems

Michael Siah, M.D. Medstar Georgetown University Hospital

Stent Graft for the Treatment of ISR:

How to do endovascular mechanical thrombaspiration

Modern treatment of SFA

The Role of Interventional Treatment for The Failing Grafts

Instent Restenosis and Occlusion: Time for Surgical Revision?

Insights from the IMPERIAL and MAJESTIC SFA Studies

Percutaneous Reconstruction of the Aortoiliac Bifurcation

Precise and Durable Outcomes With the GORE® TIGRIS® Vascular Stent

Are we using fewer Covered Stents for SFA Occlusive Disease?

Post-Surgical Care for the Individual With PAD

Branched Endovascular Therapy of the Distal Aortic Arch: Preliminary Results of the Feasibility Multicenter Trial of the Gore Thoracic Branch Endoprosthesis

Endovascular Treatment of Acute Descending Thoracic Aortic Dissections

Primary stenting of femoropopliteal atherosclerotic lesions using new helical interwoven nitinol stents Yiu Che Chan, MBBS, BSc, MD, FRCS, Stephen W.

FAIR Trial design: Patients with SFA in-stent restenosis (ISR) were randomized to either a paclitaxel-coated balloon (DCB) (dose 3.5 μg/mm2) or routine.

Results of polytetrafluoroethylene-covered nitinol stents crossing the inguinal ligament Keith D. Calligaro, MD, Praveen Balraj, MD, Neil Moudgill, MD,

ILLUMENATE Trial design: Patients with superficial femoral artery (SFA) and/or popliteal arterial stenoses were randomized in a 2:1 fashion to either balloon.

Impact of transrenal aortic endograft placement on endovascular graft repair of abdominal aortic aneurysms Michael L. Marin, MD, Richard E. Parsons,

Superficial femoral—popliteal veins and reversed saphenous veins as primary femoropopliteal bypass grafts: A randomized comparative study Martin L. Schulman,

Endovascular repair of thoracoabdominal aortic aneurysm using the off-the-shelf multibranched t-Branch stent graft Bernardo C. Mendes, MD, Gustavo S.

Treatment of complex abdominal aortic aneurysms by a combination of endoluminal and extraluminal aortofemoral grafts James May, MS, FRACS, FACS, Geoffrey.

Preliminary clinical outcome and imaging criterion for endovascular prosthesis development in high-risk patients who have aortoiliac and traumatic arterial.

Clinical significance of embolic events in patients undergoing endovascular femoropopliteal interventions with or without embolic protection devices

Outcomes of the Japanese multicenter Viabahn trial of endovascular stent grafting for superficial femoral artery lesions Takao Ohki, MD, PhD, Kimihiko.

Paclitaxel-coated balloon reduces target lesion revascularization compared with standard balloon angioplasty Nicholas Candy, MBBS, Eugene Ng, MBBS, Ramesh.

Scott S. Berman, MD, MHA, FACS, Shonda L. Banegas, DO

Four-year randomized prospective comparison of percutaneous ePTFE/nitinol self- expanding stent graft versus prosthetic femoral-popliteal bypass in the.

Randomized comparison of ePTFE/nitinol self-expanding stent graft vs prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery.

Endovascular Live Case Mount Sinai Hospital, NY

Anatomic factors associated with acute endograft collapse after Gore TAG treatment of thoracic aortic dissection or traumatic rupture Bart E. Muhs, MD,

Endovascular treatment of atherosclerotic popliteal artery disease based on dynamic angiography findings Chaoyi Cui, MD, PhD, Xintian Huang, MD, Xiaobing.

The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protégé.

Harry Spoelstra, MD, Filip Casselman, MD, Olivier Lesceu, MD

Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive.

Alternative techniques for management of distal anastomoses of aortofemoral and iliofemoral endovascular grafts Reese A. Wain, MD, Ross T. Lyon, MD,

The American College of Cardiology Presented by Dr. A. Abazid

Nicolas Mouawad, MD, Chief and Medical Director, Vascular and Endovascular Surgery, McLaren Bay Region A Tale of two lesions.

Presentation transcript:

GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc. 1 GORE VIABAHN ® Endoprosthesis Speaker’s Presentation Resource

2 Agenda Product Description Clinical Performance Propaten Bioactive Surface Latest Device Revisions GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc.

3 Product Description

4 Total Endoluminal SFA Bypass The GORE VIABAHN ® Endoprosthesis covers and seals off the diseased and irregular tissue of the arterial wall. In contrast, a bare nitinol stent covers only a small portion of the diseased arterial lumen. Individual results may vary. GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc.

5 Contoured proximal edge Propaten Bioactive Surface Endoprosthesis Description Ultra-thin wall ePTFE tube Unique, durable bonding film Polished nitinol support Lengths: 2.5, 5, 10, 15 cm Diameters: 5 – 13 mm GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc.

6 Features and Benefits Nitinol Stent –Conformable and durable ePTFE Lining –Covers diseased tissue Lower Profile –Streamlined delivery system facilitates treating challenging SFA lesions Heparin-bonded Surface –Intended to provide sustained thromboresistance Contoured proximal edge –May improve flow dynamics as blood enters endoprosthesis GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc.

7 TIP to HUB Deployment 1.Gain access to lesion with the guidewire. 2.Pre-dilate with appropriately sized balloon. 3. Confirm initial landing zone before deployment. 4.Slowly pull deployment knob in a smooth motion. 5.Seat balloon well inside device during touch-up " guidewire Guidewire AccessDevice Location Device Deployment Balloon Dilatation Balloon Touch-up 6.Land proximal edge at least 1 cm into healthy vessel. Device Location GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc.

8 Clinical Lessons Learned Avoid non-compliant lesions Ensure adequate inflow and outflow (e.g., at least one vessel run-off) Correct sizing is key Land device at least 1 cm into healthy vessel proximally and distally to the lesion Every region pre-treated with Percutaneous Transluminal Angioplasty (PTA) needs to be covered by the device During post dilatation, only balloon inside the region covered by the device Consider an antiplatelet regimen post-procedure GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc.

9 Clinical Performance

10 Reported Primary Patency of GORE VIABAHN ® Endoprosthesis in the SFA* Note: Patency definitions vary * Studies including at least 30 limbs ** Prospective randomized GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc.

11 GORE VIABAHN ® Endoprosthesis SFA Average Primary Patency* * Studies including at least 30 limbs GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc.

12 One Year Primary Patency Based on Stented Length *Studies including at least 30 limbs. Coats et al. did not report lesion length. GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc.

13 Original PMA Original prospective, randomized, multicenter PMA study comparing GORE VIABAHN ® Endoprosthesis to percutaneous transluminal angioplasty in the treatment of superficial femoral artery occlusive disease. Saxon RR, Dake MD, Volgelzang RL, Katzen BT, Becker GJ. Randomized, Multicenter Study Comparing Expanded Polytetrafluoroethylene- covered Endoprosthesis Placement with Percutaneous Transluminal Angioplasty in the Treatment of Superficial Femoral Artery Occlusive Disease. Journal of Vascular & Interventional Radiology 2008;19: Enrollment from 1998 to 1999, preceding clopidogrel availability Patency defined as freedom from target vessel revascularization and peak systolic velocity ratio < 2.0 for vessel GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc.

14 Baylor Study Prospective, randomized comparison of percutaneous GORE VIABAHN ® Devices versus prosthetic femoral-popliteal bypass in the treatment of superficial femoral arterial occlusive disease. “…similar primary patency at 24-month follow-up when compared with conventional femoral-popliteal artery bypass grafting with synthetic conduit.” McQuade K, Gable D, Hohman S, Pearl G, Theune B. Randomized comparison of ePTFE/nitinol self-expanding stent graft vs prosthetic femoral- popliteal bypass in the treatment of superficial femoral artery occlusive disease. Journal of Vascular Surgery 2009;49(1): GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc. DACRON ® is a trademark of Invista, Inc., and is licensed to Unifi Inc.

15 Saxon: Four Year Follow-up Non-randomized, single-center study investigating patency of GORE VIABAHN ® Endoprosthesis in intermediate lesion lengths with four year follow-up Saxon RR, Coffman JM, Gooding JM, Ponec DJ. Long-term Patency and Clinical Outcome of the Viabahn Stent-Grafts for Femoropopliteal Artery Obstructions. Abstract presented at the SIR 31st Annual Scientific Meeting. Journal of Vascular & Interventional Radiology 2007;18: GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc.

16 GORE VIABAHN ® Endoprosthesis with Propaten Bioactive Surface

17 Unique Bioactive Heparin Bonding Technology Heparin molecules are bonded directly to the surface of the endoprosthesis –Heparin is a polysaccharide anticoagulant with a long history of clinical use. 1 –Heparin has a potent antiproliferative effect on vascular smooth muscle cells. 2 A Gore proprietary end-point attachment mechanism (CARMEDA ® BioActive Surface Technology (CBAS ® ) allows for retention of bioactivity The result is an endoprosthesis intended to provide sustained thromboresistance 1 Hirsh J, Anand SS, Halperin JL, Fuster V. AHA Scientific statement. Guide to anticoagulant therapy: heparin. Circulation 2001;103: Clowes AW, Karnowsky MJ. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977;265: GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc. CARMEDA ® and CBAS ® are trademarks of Carmeda AB, a wholly owned subsidiary of W. L. Gore & Associates.

18 Unique Bioactive Heparin Bonding Technology Inside the microstructure Heparin molecule Bioactive heparin site Heparin molecules are bonded via end-point linkage mechanism to the surface of the endoprosthesis while retaining heparin’s activity. ePTFE fibril GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc.

19 Mechanism of Action Heparin molecules are bonded to the endoprosthesis surface Bioactive site of the heparin molecule binds to antithrombin (AT) Antithrombin (AT) binds to thrombin (T) – a neutral AT-T complex is formed Thrombin loses its ability to catalyze the conversion of fibrinogen to fibrin Neutral AT-T complex detaches from the heparin molecule Heparin bioactive site becomes available to again bind antithrombin GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc.

20 Acute Thromboresistance GORE VIABAHN ® Endoprosthesis with Propaten Bioactive Surface Control Endoprosthesis The bioactive luminal surface of a 5 mm diameter GORE VIABAHN ® Endoprosthesis with Propaten Bioactive Surface appears free of thrombus after two hours in an in vitro blood loop model. The non- bioactive luminal surface of a control endoprosthesis (5 mm diameter) appears covered with thrombus after 90 minutes in the same blood loop model. (Data on file) GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc.

21 Sustained Heparin Bioactivity Anchored to the endoprosthesis surface Bonded – does not elute Intended to provide sustained thromboresistance Begovac PC, Thomson RC, Fisher JL, Hughson A, Gällhagen A. Improvements in GORE-TEX ® Vascular Graft performance by Carmeda ® bioactive surface heparin immobilization. European Journal of Vascular and Endovascular Surgery 2003;25(5): Long-term heparin activity of explanted heparin-bonded ePTFE vascular grafts in a canine model GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc.

22 GORE VIABAHN ® with Propaten Bioactive Surface: First Data 50 limbs 24% devices were 5 mm diameter - 2.3% mean change in platelet count at 14 days No evidence of HIT 0% thrombosis at six months Chadda N, Museitif R, Djelmami-Hani M, et al. Heparin-Bonded VIABAHN Stent Graft for SFA Lesions: incidence of stent thrombosis and heparin-induced thrombocytopenia. Abstract presented at the TCT 2008: Transcatheter Cardiovascular Therapeutics 20th Annual Scientific Symposium; October , 2008; Washington, DC. American Journal of Cardiology 2008;102(8)Supplement 1:221i. GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc.

23 Latest Device Revisions

GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc. 24 A New Beginning for the Proximal End New Contoured Edge

25 New precision laser trimming technology enables manufacturing change Excess graft material is removed Contoured trim is on proximal edge only GORE VIABAHN ® Endoprosthesis: Now with Contoured Edge GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc.

26 Improves device apposition to the vessel wall when oversizing prevents device expansion to its nominal diameter – Contoured edge may improve flow dynamics at proximal end Reason for Modification GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc.

27 30 day Contoured Edge: Canine Model IVUS demonstrates device apposition to artery. Post-mortem dissection demonstrates device apposition to artery. 90 day GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc.

28 Result of a manufacturing change implementing laser edge trimming technology Excess material at the proximal edge removed The Instructions for Use, including sizing and placement recommendations remain unchanged May improve the flow dynamics of blood entering the endoprosthesis Summary of Modification GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc.

29 The Evolution of Performance

30 Streamlined Deployment for Larger Sizes 9 – 13 mm diameter endoprosthesis now incorporate the same delivery system as the 5 – 8 mm diameter devices GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc.

31 Product Comparison GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc. You knew it as GORE HEMOBAHN ® Endoprosthesis; now it is the next generation 9 – 13 mm diameter GORE VIABAHN ® Endoprosthesis with PROPATEN Bioactive Surface

32 Product Comparison GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc.

33 Large Diameter Deployment Changes HUB to TIP deployment Unrolling expansion – 0.025" guidewire compatibility TIP to HUB deployment Uniform radial expansion – " guidewire compatibility – Lower profile on some configurations GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc.

34 Currently Enrolling Clinical Studies

35 Gore VIPER Clinical Study

36 Gore VIPER Clinical Study Heparin Bonded SurfaceContoured edge

37 VIASTAR Clinical Study

38 Products listed may not be available in all markets. GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc. AL0752-EU3 SEPTEMBER 2009